Dicoumarol: A unique microtubule stabilizing natural product that is synergistic with Taxol

Cancer Research

Volumn 63, Issue 6, 2003, Pages 1214-1220

  Madari, Hamta ^a   Panda, Dulal ^b   Wilson, Leslie ^a   Jacobs, Robert S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INDIAN INSTITUTE OF TECHNOLOGY BOMBAY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

DICOUMAROL; PACLITAXEL; TUBULIN;

ANIMAL TISSUE; ARTICLE; CELL CYCLE; CELL DIVISION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; EMBRYO; IN VITRO STUDY; MICROTUBULE ASSEMBLY; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; SEA URCHIN;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATTLE; CELL DIVISION; DICUMAROL; DRUG SYNERGISM; KINETICS; MICROSCOPY, VIDEO; MICROTUBULES; PACLITAXEL; SEA URCHINS; SPECTROMETRY, FLUORESCENCE; TUBULIN;

EID: 0037444278     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Keating, G. J., and O'Kennedy, R. The chemistry and occurrence of coumarins. In: R. O'Kennedy and R. D. Thomes (eds), Coumarins: Biology, Applications and Mode of Action, pp. 23-64. West Sussex, England: John Wiley & Sons, 1997.
2. Marshall, M. E., Mohler, J. L., Edmonds, K., Williams, B., Butler, K., Ryles, M., Weiss, L., Urban, D., Beuschen, A., and Markiewicz, M. An updated review of the clinical development of coumarin (1, 2-benxopyrone) and 7-hydroxycoumarin. J. Cancer Res. Clin. Oncol., 120: 39-42, 1994.
3. Moran, E., Prosser, E., O'Kennedy. R., and Thornes, R. D. The effect of coumarin and 7-hydroxycoumarin on the growth of human tumor cell lines. J. Irish Coll. Phys. Surg., 22: 41-48, 1993.
4. Siegers, C. P., and Bostelmann, H. C. Effect of coumarin on cell cycle proliferation in human tumor cell lines. J. Irish Coll. Phys. Surg., 22: 47-50, 1993.
5. Myers, R. B., Parker, M., and Grizzle, W. E. The effects of coumarin and suramin on growth of malignant renal and prostatic cell lines. J. Cancer Res. Clin. Oncol., 120: 11-13, 1994.
6. Finn, G. J., Creaven, B., and Egan, D. A. Study of the in vitro cytotoxic potential of natural and synthetic coumarin derivatives by using human normal and neoplastic skin cell lines. Melanoma Res., 11: 461-467, 2001.
7. Feuer, G., Kellen, J. A., and Kovacs, K. Suppression of 7, 12-dimethylbenz(a)anthracene-induced breast carcinoma by coumarin in the rat. Oncology, 33: 35-39, 1976.
8. Thomes, D., Daly, L., Lynch, G., Browne, H., Tanner, A., Keene, F., O'Loughlin, S., Corrigan, T., Daly, P., Edwards, G., Breslin, B., Browne, H. Y., Shine, M., Lennon, F., Hanley, J., McMurray, N., and Gaffney, E. Prevention of early recurrence of high risk malignant melanoma by coumarin. Eur. J. Surg. Oncol., 15: 431-435, 1989.
9. Omarbasha, B., Fair, W. R., and Heston, W. D. Effect of coumarin on the normal rat prostate and on the R-3327H prostatic adenocarcinoma. Cancer Res., 49: 3045-3049, 1989.
10. Raev, L. D., Voinova, E., Ivanov, I. C., and Popov, D. Antitumor activity of some coumarin derivatives. Pharmazie, 45: 696, 1990.
11. Maucher, A., and Von Angerer, E. Antitumor activity of coumarin and 7-hydroxycoumarin against 7, 12-dimethylbenz[a]anthracene-induced rat mammary carcinomas. J. Cancer Res. Clin. Oncol., 120: 502-504, 1994.
12. Thomes, R. D., Daly, L., Lynch, G., Breslin, B., Browne, H., Browne, H. Y., Corrigan, T., Daly, P., Edwards, G., and Gaffney, E. Treatment with coumarin to prevent or delay recurrence of malignant melanoma. J. Cancer Res. Clin. Oncol., 120: S32-S34, 1994.
13. Marshall, M. E., Butler, K., and Fried, A. Phase I evaluation of coumarin (1, 2-benzopyrone) and cimetidine in patients with advanced malignancies. Mol. Biother., 3: 170-178, 1991.
14. Mohler, J. L., Gomella, L. G., Crawford, E. D., Glode, L. M., Zippe, C. D., Fair, W. R., and Marshall, M. E. Phase II evaluation of coumarin (1, 2-benzopyrone) in metastatic prostatic carcinoma. Prostate, 20: 123-131, 1992.
15. Smith, G. F., Neubauer, B. L., Sundboom, J. L., Best, K. L., Goode, Tanzer, L. R., Merriman, R. L., Frank, J. D., and Herrmann, R. G. Correlation of the in vivo anticoagulant, antithrombotic and antimetastatic efficacy of warfarin in the rat. Thromb. Res., 50: 163-174, 1988.
16. Thomes, R. D. Anticoagulant therapy in patients with cancer. J. Irish Med. Assoc., 62: 426-429, 1969.
17. Thomes, R. D. Warfarin as maintenance therapy for cancer. J. Irish Coll. Phys. Surg., 2: 41-42, 1972.
18. D'Souza, D., Daly, L., and Thomes, R. D. Levamisole. BCG and warfarin as adjuvants to chemotherapy for increased survival in advanced breast cancer. Ir. Med. J., 11: 605-608, 1978.
19. Chahinian, A. P., Propert, K. J., Ware, J. H., Zimmer, B., Perry, M., Hirsh, V., Skarin, A., and Kopel, S. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B. J. Clin. Oncol., 7: 993-1002, 1989.
20. Zacharski, L. R., Henderson, W. G., Rickles, F. R., Forman, W. B., Cornell, C. J. Jr., Forcier, R. J., Edwards, R., Headley, E., Kim, S. H., O'Donnell, J. R., O'Dell, R., Tomyos, K., and Kwaan, H. C. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA. 245: 831-835, 1981.
21. Zacharski, L. R., Henderson, W. G., Rickles, F. R., Forman, W. B., Comell, C. J. Jr. Forcier, R. J., Edwards, R. L., Headley, E., Kim, S. H., and O'Donnell, J. F. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75, Cancer, 53: 2046-2052, 1984.
22. Schulman, S., and Lindmarker, P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N. Engl. J. Med., 342: 1953-1958, 2000.
23. Podbielkowska, M., Kupidlowska, E., Waleza, M., Dobrzynska, K., Louis, S. A., Keightley, A., and Zobel, A. M. Coumarins as antimitotics. Int. J. Pharmacog., 32: 262-273, 1994.
24. Podbielkowska, M., Piwocka, M., Waszkowska, E., Waleza, M., and Zobel, A. M. Effect of coumarin and its derivatives on mitosis and ultrasturcutre of meristematic cells. Int. J. Pharmacog., 33: 7-15, 1995.
25. Wilson, L., and Jordan, M. A. Microtubule dynamics: taking aim at a moving target. Chem. Biol., 2: 569-573, 1995.
26. Saxton, W. M., Stemple, D. L., Leslie, R. J., Salmon, E. D., Zavortink, M., and McIntosh, J. R. Tubulin dynamics in cultured mammalian cells. J. Cell Biol., 99: 2175-2186, 1984.
27. Mitchison, T. J. Poleward microtubule flux in the mitotic spindle: evidence from photoactivation of fluorescence. J. Cell Biol., 109: 637-652. 1989.
28. Gliksman, N. R., Skibbens, R. V., and Salmon, E. D. How the transition frequencies of microtubule dynamic instability (nucleation, catastrophe, and rescue) regulate microtubule dynamics in interphase and mitosis: analysis using a Monte Carlo computer simulation. Mol. Biol, Cell, 4: 1035-1050, 1993.
29. Wordeman, L., and Mitchison, T. J. Dynamics of microtubule assembly in vivo. In: J. S. Hyams and C. W. Z. Lloyd (eds.), Modern Cell Biology; Microtubules, pp. 287-301. New York: Wiley-Liss, Inc., 1994.
30. Zhai, Y., Kronebusch, P. J., Simon, P. M., and Borisy, G. G. Microtubule dynamics at the G-2/M transition: Abrupt breakdown of cytoplasmic microtubules at nuclear envelope breakdown and implications for spindle morphogenesis. J. Cell Biol., 135: 201-214, 1996.
31. Jacobs, R., and Wilson, L. Fertilized sea urchin eggs as a model for detecting cell division inhibitors. Drugs Pharm. Sci., 27: 481-493, 1986.
32. Toso, R. J., Jordan, M. A., Farrell, K. W., Matsumoto, B., and Wilson, L. Kinetic stabilization of microtubule dynamic instability in vitro by vinblastine. Biochemistry, 32: 1285-1293, 1993.
33. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 248-254, 1976.
34. Panda, D., Daijo, J. E., Jordan, M. A., and Wilson, L. Kinetic stabilization of microtubule dynamics at steady state in vitro by substoichiometric concentrations of tubulin-colchicine complex. Biochemistry, 34: 9921-9929, 1995.
35. Walker, R. A., O'Brien, E. T., Pryer. N. K., Soboeiro, M. F., and Voter, W. A., Erickson, H. P., and Salmon, E. D. Dynamic instability of individual microtubules analyzed by video light microscopy: rate constants and transition frequencies. J. Cell Biol., 107: 1437-1448, 1988.
36. Sackett, D. Vinca site agents induce structural changes in tubulin different from and antagonistic to changes induced by colchicine site agents. Biochemistry, 34: 7010-7019, 1995.
37. Chou. T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
38. Panda, D., Miller, H. P., and Wilson, L. Determination of the size and chemical nature of the stabilizing "cap" at microtubule ends using modulators of polymerization dynamics. Biochemistry. 41: 1609-1617, 2002.
39. Derry, W. B., Wilson, L., and Jordan, M. A. Substoichiometric binding of taxol suppresses microtubule dynamics. Biochemistry, 34: 2203-2211, 1995.
40. Panda, D., Jordan, M. A., Chu, K. C., and Wilson, L. Differential effects of vinblastine on polymerization and dynamics at opposite microtubule ends. J. Biol. Chem., 271: 29807-29812, 1996.
41. Schiff, P. B., Fant, J., and Horwitz, S. B. Promotion of microtubule assembly in vitro by taxol. Nature, 277: 665-667, 1979.
42. Parness, J., and Horwitz, S. B. Taxol binds to polymerized tubulin in vitro. J. Cell Biol., 91: 479-487, 1981.
43. Horwitz, S. B. Mechanism of action of taxol. Trends Pharmacol. Sci., 13: 134-136, 1992.
44. Caplow, M., Shanks, J., and Ruhlen, R. How taxol modulates microtubule disassembly. J. Biol. Chem., 269: 23399-23402, 1994.
45. Rowinsky, E. K., Eisenhauer, E. A., Chaudhry, V., Arbuck, S. G., and Donehower, R. C. Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol., 20: 1-15, 1993.
46. Hudes, G. R., Greenberg, R., Krigel, R. L., Fox, S., Scher, R., Litwin, S., Watts, P., Speicher, L., Tew, K., and Comis, R. Phase II study of estramustine and vinblastine two microtubule inhibitors in hormone-refractory prostate cancer, 10: 1754-1761, 1992.
47. Hudes, G., Nathan, F., Khater, C., Haas, N., Cornfield, M., Giantonio, B., Greenberg, R., Gomella, L., Litwin, S., Ross, E., Roethke, S., and McAleer, C. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J. Clin. Oncol., 15: 3156-3163, 1997.
48. Seidman, A. D., Scher, H. I., Petrylak, D., Dershaw, D. D., and Curley, T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J. Urol., 147: 931-934, 1992.
49. Cocconi, G., Mambrini, A., Quarta, M., Vasini, G., Bella, M. A., Ferrozzi, F., and Beretta, M. D. Vinorelbine combined with paclitaxel infused over 96 hours (VI-TA-96) for patients with metastatic breast carcinoma. Cancer (Phila.), 88: 2731-2738, 2000.
50. Kelly, W. K., Curley, T., Slovin, S., Heller, G., McCaffrey, J., Bajorin, D., Ciolino, A., Regan, K., Schwartz, M., Kantoff, P., George, D., Oh, W., Smith, M., Kaufman, D., Small, E. J., Schwartz, L., Larson, S., Tong, W., and Scher, H. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J. Clin. Oncol., 19: 44-53, 2001.
51. Panda, D., Miller, H. P., Islam, K., and Wilson, L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc. Natl. Acad. Sci. USA, 94: 10560-10564, 1997.
52. Zobel, A. M., and Schellenberger, S. E. Paclitaxel in combination with coumarin as a potentially effective anticancer agent. Pharm. Biol., 38: 192-196, 2000.
53. Bae, S., Arand, G., Azzam, H., Pavasant, P., Torri, J., Frandsen, T. L., and Thompson, E. W. Molecular and cellular analysis of basement membrane invasion by human breast cancer cells in Matrigel-based in vitro assays. Breast Cancer Res. Treat., 24: 241-255, 1993.
54. Belotti, D., Nicoletti, I., Vergani, V., Rieppi, M., Drudis, T., Viale, G., Giavazzi, R., and Taraboletti, G. Paclitaxel (Taxol), a microtubule affecting drug, inhibits tumor induced angiogenesis. Proc. Am. Assoc. Cancer Res. Annu. Meet., 37: 57, 1996.
55. Stearns, M. E., and Wang, M. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res., 52: 3776-3781, 1992.
56. Fernandez-Patrons, C., Zhang, Y., Radomski, M. W., Hollenberg, M. D., and Davidge, S. T. Rapid release of matrix metalloproteinase (MMP)-2 by thrombin in the rat aorta: modulation by protein tyronise kinase/phosphatase. Thromb. Haemost., 82: 1353-1357, 1999.
57. Mousa, S. A., and Mohamed, S. Anti-angiogenesis and anti-tumor efficacy of warfarin in the chick chorioallantoic membrane (CAM) model. Blood, 96: 182b, 2000.
58. Lau, D. H., Xue, L., Young, L. J., Burke, P. A., and Cheung, A. T. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother. Radiopharm., 14: 31-36, 1999.